144510-94-1

Basic information

• Product Name: 6,9-bis<<2-ethyl>amino>benzoisoquinoline-5,10-dione
• Synonyms: 6,9-bis<<2-ethyl>amino>benzoisoquinoline-5,10-dione
• CAS NO: 144510-94-1
• Molecular Weight: 525.605
• Mol File: 144510-94-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 6,9-bis<<2-ethyl>amino>benzoisoquinoline-5,10-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 6,9-bis<<2-ethyl>amino>benzoisoquinoline-5,10-dione(144510-94-1)
• EPA Substance Registry System: 6,9-bis<<2-ethyl>amino>benzoisoquinoline-5,10-dione(144510-94-1)

Safety Data

• Hazardous Substances Data: 144510-94-1(Hazardous Substances Data)

Usage

Uses

Pixantrone-bis-(2’-N-boc) is an antineoplastic drug belonging to group of antitumor antibiotics. Pixantrone-bis-(2’-N-BOC) is an analogue of Pixantrone (P552500).

Upstream product

• 57260-73-8 N-BOC-1,2-diaminoethane 
• 153444-55-4 leuco-2-azaquinizarin 
• 144511-13-7 6,9-difluorobenzoisoquinoline-5,10-dione 
• 4589-37-1 6,9-dihydroxybenzo[g]isoquinoline-5,10-dione 
• 123-31-9 hydroquinone 
• 490-11-9 3,4-pyridinecarboxylic acid 
• 4664-08-8 cinchomeronic anhydride 

Downstream Products

• 144675-97-8 Pixantrone maleate 

Relevant articles and documents

6, 9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5, 10-dione dimaleate and synthesis technology thereof

The invention discloses a synthesis technology of 6, 9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5, 10-dione dimaleate and relates to the technical field of antineoplastic drug synthesis. The synthesis technology comprises that 3, 4-pyridinedicarboxylic anhydride and hydroquinone undergo a reaction in the presence of a catalyst to produce a first intermediate, the first intermediate and N-t-butoxycarbonylethylenediamine undergo a reaction to produce a second intermediate, the second intermediate is subjected to deprotection, and the product and maleic acid undergo a salt forming reaction to produce a product. The prepared product has purity greater than 99.5% and known single impurity and unknown single impurity contents less than 0.1%. The important intermediate of the synthesis technology has stable properties and is convenient for storage. The synthesis technology allows mild reaction conditions, has simple processes, realizes a low cost and is suitable for industrial production. The invention also provides pixantrone dimaleate. The pixantrone dimaleate can be processed to form a freeze-dried powder injection for treating human aggressive non-Hodgkin's lymphoma with easy recurrence and high treatment difficulty.

6,9-Bisbenzoisoquinoline-5,10-diones. A Novel Class of Chromophore-Modified Antitumor Anthracene-9,10-diones: Synthesis and Antitumor Evaluations

Synthetic procedures have been developed which lead to the 2-aza congeners 3 and several related N-oxides 4.The analoques 3 exhibited a wide range of in vitro cytotoxicity against L1210 leukemia, the human colon adenocarcinoma cell line LoVo, and the doxorubicin resistant LoVo/DX cell line.Selected analogues of 3 showed significant P388 antileukemic activity in mice with 3c exhibiting high activity.This activity was also retained in the related N-oxide 4a.These heterocyclic bioisosteric models are representative of the first anthracene-9,10-diones which display antileukemic activity comparable to mitoxantrone.